"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 4 | 0 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 0 | 3 |
| 2000 | 5 | 1 | 6 |
| 2001 | 4 | 1 | 5 |
| 2002 | 7 | 1 | 8 |
| 2004 | 5 | 1 | 6 |
| 2005 | 2 | 0 | 2 |
| 2006 | 6 | 1 | 7 |
| 2007 | 3 | 2 | 5 |
| 2008 | 5 | 0 | 5 |
| 2009 | 6 | 1 | 7 |
| 2010 | 4 | 0 | 4 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 1 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021. JAMA. 2024 02 13; 331(6):524-526.
-
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings. PLoS One. 2022; 17(10):e0276066.
-
Pharmacological investigations of effort-based decision-making in humans: Naltrexone and nicotine. PLoS One. 2022; 17(10):e0275027.
-
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey. Soc Sci Med. 2022 07; 305:115034.
-
Use of Anticraving Agents in the Treatment of Exhibitionism and Frotteuristic Disorder. J Clin Psychopharmacol. 2021 Sep-Oct 01; 41(5):611-612.
-
Medical Management of Opioid-Induced Constipation. JAMA. 2019 12 10; 322(22):2241-2242.
-
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. Alcohol Alcohol. 2019 Jan 09; 54(5):559-565.
-
Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 01; 130(1):142-148.
-
Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin. 2018 Jul; 36(3):245-258.
-
State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatr Serv. 2018 04 01; 69(4):448-455.